OAS1 抗体 (AA 296-395)
Quick Overview for OAS1 抗体 (AA 296-395) (ABIN7142170)
抗原
See all OAS1 抗体适用
宿主
克隆类型
标记
应用范围
- 
    - 
                                            抗原表位
- AA 296-395
- 
                                            交叉反应
- 人
- 
                                            纯化方法
- >95%, Protein G purified
- 
                                            免疫原
- Recombinant Human 2\'-5\'-oligoadenylate synthase 1 protein (296-395AA)
- 
                                            亚型
- IgG
 
- 
                                            
- 
    
- 
    - 
                                            应用备注
- Recommended dilution: IHC:1:20-1:200,
- 
                                            限制
- 仅限研究用
 
- 
                                            
- 
    - 
                                            状态
- Liquid
- 
                                            缓冲液
- 
                        Preservative: 0.03 % Proclin 300
 Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4
- 
                                            储存液
- ProClin
- 
                                            注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 
                                            储存条件
- -20 °C,-80 °C
- 
                                            储存方法
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
 
- 
                                            
- 
    - OAS1 (2',5'-Oligoadenylate Synthetase 1, 40/46kDa (OAS1))
- 
                                            别名
- OAS1
- 
                                            背景
- 
                        Background: Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes higher oligomers of 2\'-5\'-oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. The secreted form displays antiviral effect against vesicular stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and encephalomyocarditis virus (EMCV) and stimulates the alternative antiviral pathway independent of RNase L. Aliases: (2 5')oligo(A) synthetase 1 antibody, (2-5'')oligo(A) synthase 1 antibody, 2 5 Oligoadenylate Synthetase 1 antibody, 2 5' oligo A synthase 1 antibody, 2 5' oligo A synthetase 1 antibody, 2 5A synthase 1 antibody, 2 5A synthetase 1 antibody, 2' 5' oligo A synthetase 1 antibody, 2' 5' oligoadenylate synthetase 1 40/46 kDa antibody, 2' 5' oligoadenylate synthetase 1 antibody, 2' 5' oligoisoadenylate synthetase 1 antibody, 2''-5''-oligoadenylate synthase 1 antibody, 2'5' oligo A synthetase 1 antibody, 2'5' oligoadenylate synthetase 1 antibody, 2'5' oligoisoadenylate synthetase 1 antibody, 2-5A synthase 1 antibody, E18/E16 antibody, IFI 4 antibody, IFI4 antibody, OAS 1 antibody, OAS1 antibody, OAS1_HUMAN antibody, OIAS antibody, OIASI antibody, p46/p42 OAS antibody 
- 
                                            UniProt
- P00973
- 
                                            途径
- Hepatitis C
 抗原
- 
                    
 
                                     
                                     
                                    